Boltz PBC

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Boltz PBC - overview

Established

2025

Location

Boston, Massachusetts, US

Primary Industry

Biotechnology

About

Based in the US, Boltz PBC specializes in AI-powered drug discovery, providing innovative solutions that streamline the drug development process through advanced technology and intelligent models. Founded in 2025 in Boston, US, Boltz PBC focuses on AI-driven drug discovery solutions. In November 2026, Boltz PBC raised USD 110 million in series A funding led by returning investor Andreessen Horowitz. The founder's history and previous entrepreneurial ventures are not available.


Boltz specializes in AI-powered drug discovery solutions, primarily through its Boltz Platform, which combines advanced AI models and intelligent agents to support the drug development process from hit identification to lead optimization. The platform allows scientists to define biological targets, perform extensive screenings, and integrate experimental data for refined results. Key offerings include the Boltz-1 co-folding model, Boltz-2 affinity prediction model, and BoltzGen binder design model, catering to biotech firms, pharmaceutical companies, and academic institutions across North America, Europe, and Asia. Boltz generates revenue primarily through subscriptions and partnerships with research organizations and pharmaceutical companies, offering access to its AI-driven platform for drug discovery.


Clients subscribe to tiered services that include proprietary models and expert support, establishing a steady revenue stream as the company expands its clientele within the life sciences sector. In November 2026, Boltz PBC raised USD 110 million in series A funding led by returning investor Andreessen Horowitz.


Current Investors

Andreessen Horowitz, Amplify Partners, Zetta Venture Partners, Obvious, Factorial Capital

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy

Website

www.boltz.com

Verticals

Artificial Intelligence

Company Stage

Series A

Total Amount Raised

Subscriber access only

Boltz PBC - deals

Deals TypeDeal StatusTarget (s)Deal DateInvestor(s)Seller(s)Deal size (Mn)Enterprise value (Mn)Post-money valuation (Mn)EBITDA multiple (x)Revenue multiple (x)Lead partner (s)
Series ACompletedBoltz PBC-
SeedCompletedBoltz PBC-

Displaying 1 - 2 of 2

GoingPro

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.